AT-406 (SM-406): Orally Bioavailable IAP Inhibitor for Apoptosis Activation in Cancer Cells

Executive Summary: AT-406 (SM-406, A3019) is a potent, orally bioavailable inhibitor of apoptosis proteins (IAPs), specifically targeting XIAP, cIAP1, and cIAP2, with nanomolar affinity (Ki = 66.4 nM, 1.9 nM, and 5.1 nM, respectively) [APExBIO product page]. It induces rapid cIAP1 degradation and activates caspase-dependent apoptosis across cancer cell types (bioRxiv 2024). In vitro, AT-406 demonstrates IC50 values of 0.05–0.5 μg/mL in human ovarian cancer cell lines and enhances carboplatin sensitivity. In vivo, it prolongs survival and suppresses tumor growth in mouse xenograft models. Early clinical data show oral AT-406 is well tolerated up to 900 mg in cancer patients.

Biological Rationale

Inhibitor of apoptosis proteins (IAPs) are a family of apoptosis suppressors that inhibit caspases 3, 7, and 9, thereby regulating programmed cell death, cell cycle, and signal transduction pathways (bioRxiv 2024). Overexpression of IAPs is implicated in tumor survival, chemoresistance, and immune evasion. Targeting IAPs restores apoptotic response, sensitizing cancer cells to conventional therapies and immune-mediated killing. AT-406 (SM-406) serves as a next-generation, small-molecule IAP antagonist that overcomes limitations of earlier compounds by providing oral bioavailability and high specificity. This enables robust mechanistic dissection and translational application in apoptosis modulation and cancer biology research.

Mechanism of Action of AT-406 (SM-406)

AT-406 is a Smac mimetic designed to antagonize the BIR3 domain of XIAP, cIAP1, and cIAP2. It binds XIAP with a Ki of 66.4 nM, cIAP1 at 1.9 nM, and cIAP2 at 5.1 nM, displacing endogenous inhibitors and allowing caspase activation (APExBIO). AT-406 rapidly induces proteasomal degradation of cIAP1, leading to downstream activation of caspase-3, -7, and -9, and triggering apoptosis in cancer cells. The compound also sensitizes cells to extrinsic death receptor ligands (e.g., TNF-α) and chemotherapeutics such as carboplatin. This dual action—direct induction of apoptosis and chemosensitization—expands its utility in both mechanistic studies and therapeutic modeling. For a strategic comparison to related Smac mimetics and advanced discussion on structure-activity relationships, see AT-406 (SM-406): Uncovering IAP Inhibitor Roles in Cancer..., which this article expands by providing updated quantitative benchmarks and clinical tolerability data.

Evidence & Benchmarks

• AT-406 (SM-406) inhibits XIAP, cIAP1, and cIAP2 with Ki values of 66.4 nM, 1.9 nM, and 5.1 nM, respectively, measured via biochemical binding assay at 25°C, pH 7.4 (APExBIO).
• In ovarian cancer cell lines, AT-406 induces apoptosis with IC50 values of 0.05–0.5 μg/mL (24 h, 37°C, serum-containing media) (APExBIO).
• AT-406 treatment (0.1–3 μM, 24 h) increases caspase-3 and -7 activity and PARP cleavage in vitro (Advancing IAP Inhibition...).
• Co-administration of AT-406 and carboplatin results in synergistic cytotoxicity in ovarian cancer cell models (APExBIO).
• Oral AT-406 (SM-406) exhibits bioavailability >50% in mouse and rat pharmacokinetic studies (AUC, single dose, fasted) (APExBIO).
• In vivo, AT-406 significantly inhibits tumor growth and prolongs survival in ovarian and breast cancer xenograft mouse models (dosed 10–100 mg/kg/day, oral gavage, 21 days) (APExBIO).
• Human clinical studies report oral AT-406 is well tolerated at doses up to 900 mg/day with manageable adverse events (APExBIO).
• IAP inhibition by AT-406 can restore apoptotic response in models of immune evasion, building upon insights from host-pathogen CRISPR screens (bioRxiv 2024).

For an integrated, translational perspective on how these benchmarks inform research and therapeutic innovation, see AT-406 (SM-406): Translating Mechanistic Apoptosis Insights.... This article extends prior analyses by correlating quantitative in vitro and in vivo findings with dosing and workflow recommendations.

Applications, Limits & Misconceptions

AT-406 (SM-406) is used in cancer research to dissect apoptosis pathways, model chemosensitization, and explore IAP signaling dynamics. It is valuable for:

• In vitro mechanistic studies of caspase activation and apoptosis induction.
• Evaluating IAP inhibitor synergy with DNA-damaging agents (e.g., carboplatin) in ovarian and breast cancer models.
• Preclinical in vivo models assessing tumor growth inhibition and survival benefit.
• Target validation in studies of immune evasion and cell death regulatory networks.

Common Pitfalls or Misconceptions

• AT-406 is not effective in cell types lacking functional caspase pathways or in tumors with apoptosome defects.
• Water insolubility limits direct aqueous formulation; DMSO or ethanol (≥27.65 mg/mL) is required for stock preparation.
• Chronic exposure may induce compensatory upregulation of non-targeted IAP family members, reducing efficacy.
• Not all tumors overexpress IAPs; lack of IAP dependency predicts limited AT-406 responsiveness.
• AT-406 is not suitable for long-term stock solutions; stability is optimal at -20°C and for short-term use only.

For a strategic discussion of these boundaries and mechanistic nuances, see Redefining Apoptosis Modulation: Strategic Insights for Translational Research, which this article clarifies by providing updated stability data and workflow integration tips.

Workflow Integration & Parameters

For optimal results, AT-406 (SM-406) should be dissolved in DMSO or ethanol to prepare concentrated stocks (≥27.65 mg/mL), stored at -20°C, and used within one week. Typical in vitro experiments treat cancer cell lines at 0.1–3 μM for 24 hours to analyze cell death and caspase activity. For in vivo studies, oral administration of 10–100 mg/kg/day for up to 21 days is standard in mouse xenograft models. Quality control includes batch verification of molecular weight (561.71 Da) and solid-state purity. Always ensure compatibility with downstream readouts (e.g., caspase assays, flow cytometry). For further workflow design and dosing strategies, consult Translating Apoptosis Mechanisms into Therapeutic Opportunity, which this article updates with current product handling and stability recommendations.

Conclusion & Outlook

AT-406 (SM-406) from APExBIO is a validated, orally bioavailable IAP inhibitor with robust, quantitative evidence supporting its use as a research tool in apoptosis modulation and cancer biology. Its mechanistic specificity, favorable pharmacokinetics, and clinical tolerability make it a benchmark compound for translational studies. Ongoing research aims to further delineate its role in immune evasion, combinatorial therapy, and biomarker-driven patient selection. For product details and ordering, visit the official AT-406 (SM-406) page.